Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04361825 | Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects(SUKSES-N4) | completed | Phase 2 | 42 | Se-Hoon LeeOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04939662 | Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects(SUKSES-B2) | completed | Phase 2 | 25 | Se-Hoon LeeOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04271384 | Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer | completed | Phase 2 | 25 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 24 | Shadia Jalal, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03845270 | Her2-positive Lung Cancer Treated With Dedicated Drug(R2D2) | completed | Phase 2 | 46 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04311034 | A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 37 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03014648 | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 28 | Liza Villaruz, MDOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02716038 | Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | completed | Phase 2 | 39 | Columbia UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02580994 | Pembrolizumab in Untreated Extensive SCLC(REACTION) | completed | Phase 2 | 125 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02183883 | Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity(DARWIN1) | completed | Phase 2 | 12 | University College, LondonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03409458 | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab(PAVE-1) | completed | Phase 1 / Phase 2 | 68 | Promontory Therapeutics Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT02407171 | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | completed | Phase 1 / Phase 2 | 61 | Yale UniversityOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02321540 | A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT01750281 | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.(SELECT-2) | completed | Phase 2 | 212 | AstraZenecaINDUSTRY | 8 | Oct 24, 2023 | clinicaltrials |
| NCT03727724 | Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer(AFACET) | completed | Phase 2 | 37 | The Netherlands Cancer InstituteOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03434418 | A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations | completed | Phase 2 | 17 | Duke UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03468985 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00590902 | Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT02426658 | Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02904954 | Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | completed | Phase 2 | 60 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT00602797 | Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02803203 | Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02439450 | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | Heat BiologicsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04790409 | Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations | completed | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT02343952 | Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | completed | Phase 2 | 93 | Nasser Hanna, M.D.OTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT04345146 | Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC | completed | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03083808 | Phase II Trial of Continuation Therapy in Advanced NSCLC | completed | Phase 2 | 35 | Greg Durm, MDOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT03513666 | A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment(JS001) | completed | Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT03840915 | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 70 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Aug 21, 2023 | clinicaltrials |
| NCT00003692 | Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 2 | 128 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 18, 2023 | clinicaltrials |
| NCT00245154 | Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 296 | NCIC Clinical Trials GroupNETWORK | 6 | Aug 4, 2023 | clinicaltrials |
| NCT00869752 | MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 12 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01068587 | MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy | completed | Phase 1 / Phase 2 | 31 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01708993 | Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy | completed | Phase 2 | 166 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03520842 | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT02980991 | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | completed | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT01833572 | Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | completed | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT00062010 | Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | completed | Phase 2 | 37 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00828009 | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 70 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00057837 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 140 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 3, 2024source: clinicaltrials